Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine

Annals of Hematology

Volumn 91, Issue 10, 2012, Pages 1547-1554

  Wu, Lingyun ^a   Li, Xiao ^a   Xu, Feng ^a   Chang, Chunkang ^a   He, Qi ^a   Zhang, Zheng ^a   Zhang, Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Decitabine; Myelodysplastic syndrome; Ribosomal protein L23

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HOMOHARRINGTONINE; MESSENGER RNA; RIBOSOME PROTEIN; RIBOSOME PROTEIN L23; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CD34 SELECTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RETROSPECTIVE STUDY; RIBOSOME PROTEIN L23 GENE; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR GENE; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; CELL TRANSFORMATION, NEOPLASTIC; CYTARABINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HARRINGTONINES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RIBOSOMAL PROTEINS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867328193     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1486-2     Document Type: Article

References (24)

1. Nimer SD (2008) Myelodysplastic syndromes. Blood 111:4841-4851
2. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A et al (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276
3. Li X, Bryant E, Deeg HJ (2004) Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 80:140-145
4. Warner JR, Mclntosh (2009) How common are extraribosomal functions of ribosomal proteins? Mol Cell 34:3-11
5. Jin A, Itahana K, O'Keefe K, Zhang Y (2004) Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24:7669-7680
6. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H (2004) Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24:7654-7668
7. Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG, EilersM(2008) A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat Cell Biol 10:1051-1061
8. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL (2009) Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 114:4847-4858
9. Delacrétaz F, Schmidt PM, Piguet D, Bachmann F, Costa J (1987) Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 87:180-186
10. Jaffe E, Harris N, Stein H, Vardiman J (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, ARC, Lyon
11. Valent P, Horny HP (2009) Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 39:548-553
12. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
13. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis inmyelodysplastic syndromes. Blood 89:2079-2088
14. Wattel E, De Botton S, Luc Laï J, Preudhomme C, Lepelley P, Bauters F, Fenaux P (1997) Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 98:983-991
15. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fière D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E, EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center (2002) Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16:1615-1621
16. Poulain S, Lepelley P, Preudhomme C, Cambier N, Cornillon J, Wattel E, Cosson A, Fenaux P (2000) Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 110:591-598
17. Kurata M, Hasegawa M, Nakagawa Y, Abe S, Yamamoto K, Suzuki K, Kitagawa M (2006) Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. Exp Mol Pathol 81:249-254
18. Shi Y, Zhai H, Wang X, Han Z, Liu C, Lan M, Du J, Guo C, Zhang Y, Wu K, Fan D (2004) Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing druginduced apoptosis. Exp Cell Res 296:337-346
19. Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A (2004) CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance- associated phenotypes. Clin Cancer Res 10:7599-7606
20. Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q (2009) Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 50:1461-1467
21. Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q (2011) Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 137:1563-1569
22. Jin J, Jiang DZ, MaiWY, Meng HT, QianWB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20:1361-1367
23. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842-3848
24. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, LinkKA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T,Maciejewski J,Mulloy JC, Saunthararajah Y(2011) p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 25:1739-1750